Companies in #Immuno-Oncology (BXCL701)
Found 1 company operating in this sector.
BioXcel Therapeutics (rebranding to BX Liquidation, Inc.) was a clinical-stage biopharmaceutical company that leveraged artificial-intelligence–driven drug discovery to develop neuroscience and immuno-oncology medicines. Following its August 2026 Chapter 11 bankruptcy filing, on October 30, 2026 BioXcel completed the sale of substantially all assets relating to its lead commercial product IGALMI (sublingual dexmedetomidine) to Teva Pharmaceuticals for $57.5 million cash. Concurrently, the Board terminated the employment of its entire executive leadership team (CEO Vimal Mehta, CFO Richard Steinhart, CSO Frank Yocca, and CLO Javier Rodriguez) effective October 31, 2026, transitioned management to Chief Restructuring Officer Samir Saleem as President and Secretary, and authorized changing the company name to BX Liquidation, Inc. to formally wind down and liquidate remaining corporate affairs.